Eb-Dnk102 Dual-Targeting Car-Nk Cells
Pancreatic Ductal Adenocarcinoma
Explore 280 assets in Pancreatic Ductal Adenocarcinoma →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Beijing Biotech
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07627711CT.gov Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | — | Recruiting | — | — | — |
NCT07480928CT.gov Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Ductal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eb-Dnk102 Dual-Targeting Car-Nk Cells (this asset) | Beijing Biotech | P1/2 | CC · 43 |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | OHSU Knight Cancer Institute | P2 | BB |
| Rmc-6236 | Tango Therapeutics, Inc. | P3 | BB |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
| S-1 | Genentech, Inc. | P2 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone | Corcept Therapeutics | P3 | BB |
| Ivospemin | Panbela Therapeutics, Inc. | P2/3 | BB |
| Metformin | British Columbia Cancer Agency | P2 | BB |
+42 more in the Pancreatic Ductal Adenocarcinoma cohort
Other indications for Eb-Dnk102 Dual-Targeting Car-Nk Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerOHSU Knight Cancer InstituteBB
- Rmc-6236Tango Therapeutics, Inc.BB
- DaraxonrasibRevolution Medicines, Inc.BB
- S-1Genentech, Inc.BB
- OxaliplatinJonsson Comprehensive Cancer CenterBB
Citation
Floatz Terminal. Eb-Dnk102 Dual-Targeting Car-Nk Cells in Pancreatic Ductal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eb-dnk102-dual-targeting-car-nk-cells-pancreatic-ductal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →